Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.4K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.4K
Hepatitis01:25

Hepatitis

46
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
Subviral Agents01:29

Subviral Agents

850
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
850

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cyclometalated Gold(III) Complex Targets Mitochondrial VDAC1 to Drive Immunometabolic Reprogramming in Cancer.

Journal of the American Chemical Society·2026
Same author

Editorial: New insights into gut microbiota in colorectal cancer.

Frontiers in cellular and infection microbiology·2026
Same author

Implementation of tuberculosis care cascade among adult people living with HIV registered in anti-retroviral therapy centres in Odisha, India, 2020-2023.

BMC infectious diseases·2026
Same author

Young Female With Shortness of Breath.

Journal of the American College of Emergency Physicians open·2025
Same author

Phosphatidylinositol 3-Kinase Signaling Enhances Intestinal Crypt Epithelial Cell Recovery after Radiation.

The American journal of pathology·2025
Same author

Mitochondrial function and gastrointestinal diseases.

Nature reviews. Gastroenterology & hepatology·2024

Related Experiment Video

Updated: Apr 8, 2026

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K

Recombinant Hepatitis E virus like particles can function as RNA nanocarriers.

Subrat Kumar Panda1, Neeraj Kapur2, Daizy Paliwal3

  • 1Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. subrat@gmail.com.

Journal of Nanobiotechnology
|June 25, 2015
PubMed
Summary

Hepatitis E virus (HEV) virus-like particles (VLPs) can deliver RNA into specific cells and elicit immune responses. This demonstrates their potential as a non-replicative gene delivery system beyond vaccine applications.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K

Related Experiment Videos

Last Updated: Apr 8, 2026

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Virus-like particles (VLPs) mimic virions and are effective vaccine candidates.
  • Hepatitis E virus (HEV) VLPs, produced from E. coli expressed capsid protein (pORF2), have been previously characterized for in vitro assembly and cellular entry.
  • HEV VLPs (Hecolin) are being developed as a vaccine against Hepatitis E.

Purpose of the Study:

  • To investigate the use of HEV VLPs as a carrier for heterologous RNA.
  • To determine if encapsulated RNA can be expressed in target cells and elicit an immune response in vivo.

Main Methods:

  • In vitro transcribed RNA encoding red fluorescent protein (RFP) or Hepatitis B virus surface antigen (HBsAg), fused to the HEV 5' region, was packaged into HEV pORF2-VLPs.
  • The resulting VLPs were incubated with various cell lines (Huh7, A549, Vero, HeLa, SiHa) to assess cellular uptake.
  • Balb/c mice were immunized with HEV VLPs encapsulating HBsAg RNA, and immune responses against HEV capsid protein and HBsAg were measured.

Main Results:

  • HEV pORF2-VLPs specifically transferred exogenous coding RNA into Huh7 and A549 cells.
  • Immunization of mice with HEV-VLPs carrying HBsAg RNA elicited a humoral immune response against both the HEV capsid protein and the HBsAg protein.
  • These results confirm the successful packaging, delivery, and expression of heterologous RNA using HEV VLPs.

Conclusions:

  • HEV pORF2-VLPs demonstrate potential as a non-replicative, tissue-specific gene delivery system.
  • Beyond their vaccine potential, HEV VLPs can be utilized for therapeutic gene delivery applications.